Co-Founder & Scientific Advisor, Vir Biotechnology
Search every verified Louis Picker interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Louis Picker, a professor at Oregon Health and Science University and co-founder and scientific advisor of Vir Biotechnology, has been involved in research on HIV/SIV immunotherapeutics and vaccine development. In a June 2025 presentation, Picker described studies testing the hypothesis that neutralizing antibodies given at the time of antiretroviral therapy release could delay viral rebound in SIV-infected macaques. He stated that while the antibodies significantly delayed rebound, they did not provide enhanced post-treatment viral control or a functional vaccine effect. Picker also discussed a T-cell vaccine targeting the gag protein, which he said delayed viral rebound and reduced post-treatment viral loads, suggesting a need for more aggressive T-cell vaccine approaches. Picker has also commented on the broader landscape of infectious disease research and vaccine development. In a 2021 interview, he noted that the rapid development of COVID-19 vaccines was enabled by long-term investments in vaccine and gene therapy research, and he expressed support for continued and increased investment in vaccine science. He has described his work on a cytomegalovirus (CMV)-based vector for HIV as showing durable efficacy in monkey models, with protection lasting over six years in some cases. Picker has stated that a human CMV vector is being developed for clinical trials through Vir Biotechnology.
“Antiretroviral therapy is perhaps certainly one of the top three medical breakthroughs of modern times, converting a deadly disease like HIV/AIDS into a treatable condition where people have essentially normal lifespans.”
“Neutralizing antibodies given at the time of antiretroviral therapy release significantly delay time to viral rebound, demonstrating that these antibodies work as advertised in limiting viral spread.”
“Despite delaying viral rebound, neutralizing antibodies did not provide enhanced post-antiretroviral viral control or evidence of a functional vaccine effect, even when combined with checkpoint blockade therapy.”
“The rebound dynamics indicate that fully suppressive levels of neutralizing antibodies act like antibody-mediated antiretroviral therapy, which could be useful for patients needing drug holidays.”
... hear about that today from Louis picker from OHSU sorry Oregon Health and Science University and Lewis's title is investigation ...
George Scangos, Vir Biotechnology president & CEO, joins 'Power Lunch' in an interview with CNBC's Meg Tirrell after Vir ...
OHSU professor will sign off on COVID-19 vaccine.
Vir Biotechnology CEO George Scangos talks with CNBC's Meg Tirrell to break down the company's outlook. For access to live ...
Current Status and Future Enhancements to Animal Models for AIDS Research September 23-24, 2019 The Office of AIDS ...
David Margolis, MD, University of North Carolina, Chapel Hill, NC; Louis Picker, MD, Oregon Health and Sciences University, Portland, OR; Panel Host – Matt Sharp, HIV Cure Research Advocate, San Francisco, CA Description of the various approaches being taken, today in isolation and potentially in combination in the future, to seek a cure for HIV including exposing and eliminating latent HIV reservoirs, therapeutic and preventive vaccine research, and introduction of novel antibodies in a therapeutic capacity. To view this and other videos be sure to subscribe to stay up to date. You can also…
Date: September 27, 2013 Speakers: Dr. Louis Picker, Associate Director of OHSU's Vaccine and Gene Therapy Institute and ...
The OHSU Effect: Inside Health & Science aires each week on KXL 101.1 FM in Portland Oregon. Visit www.theohsueffect.org for ...
Um the virus at these early time points of infection most of the vaccines that have been made all uh have responses that come in ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Louis Picker.